Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia
AUTOR(ES)
Khodashenas, Maryam; Rajabian, Arezoo; Attaranzadeh, Armin; Lavi Arab, Fahimeh; Allahyari, Negin; Allahyari, Abolghasem
FONTE
Revista da Associação Médica Brasileira
DATA DE PUBLICAÇÃO
2022
RESUMO
SUMMARY OBJECTIVE: This study aimed to assess the patterns of serum cytokines in chronic lymphocytic leukemia patients at baseline and post-chemotherapy and investigate their association with response to treatment and chronic lymphocytic leukemia prognosis. METHODS: Blood samples were taken from 32 subjects at their first medical visit after being diagnosed with chronic lymphocytic leukemia and 1 year after chemotherapy. Then, levels of cytokines and blood parameters in peripheral blood were measured. Correlation analysis was used to assess the indexes before and after chemotherapy as well as at different disease stages. RESULTS: Most of the patients (45.80%) had stages I and III before initiation of treatment and after treatment, respectively. There were significant differences between levels of interleukin (IL)-6 (p=0.006) and IL-10 (p=0.009) before and after treatment. Notably, the difference in IL-10 levels before and after treatment was significantly higher in the advanced stages compared to that in the non-advanced stages (p=0.007). IL-6 and IL-10 were also higher in the expired patients compared to the survived cases. CONCLUSIONS: Cytokines such as IL-6 and IL-10 may be considered predicting factors for chronic lymphocytic leukemia prognosis.
Documentos Relacionados
- Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques
- Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia
- Wells syndrome associated with chronic lymphocytic leukemia
- Membrane difference in peripheral blood lymphocytes from patients with chronic lymphocytic leukemia and Hodgkin's disease.
- Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia